ROIV News and Press, Roivant Sciences Ltd. From 09/13/23

2023-09-13 00:33:55 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased from $21.31B to $24.43B this quarter. The number of holdings in the portfolio increased from 49 to 86. The largest five individual stock positions in the portfolio are Visa, Danaher, APi...

2023-09-11 13:08:20 ET Summary Roivant, a biopharmaceutical firm, focuses on inflammation and immunology, especially VTAMA for dermatology, showing significant growth. With strong financials, clinical successes, and a $9.72B market cap, Roivant has consistently outperformed the S&...

BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it completed the redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants&#x...

2023-09-09 11:17:21 ET Roivant Sciences (NASDAQ: ROIV) stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since December 2021. It has roared back by more t...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-28 18:00:00 ET If you are looking for some high-octane growth stocks to add to your portfolio, you might want to follow in the footsteps of some of the most successful investors in the biotech sector. Baker Bros. Advisors, a hedge fund founded by billionaire brothers Julian and Feli...

BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants&#...

2023-08-14 20:20:21 ET Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Conference Call August 14, 2023 08:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matthew Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief In...

2023-08-14 07:27:35 ET Roivant Sciences press release ( NASDAQ: ROIV ): FQ1 GAAP EPS of -$0.38 misses by $0.07 . Revenue of $21.62M (+400.5% Y/Y) misses by $2.87M . Roivant reported its consolidated cash, cash equivalents and restricted cash of $1.4B at June 30...

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses First patient has been dosed in the TAHOE study, a global Phase 2 trial of RVT-3...